Dec. 3, 2019: Astellas Pharma Inc. announced the presentation of new data in acute myeloid leukaemia (AML) at the 61st American Society of Hematology (ASH) Annual Meeting(Dec. 7-10) in Orlando, Fla.
Seven abstracts sponsored from Astellas focus on patients with relapsed (a disease that has returned) or refractory (resistant to treatment) AML through an FLT3 mutation (FLT3mut+).
New findings from abstracts include the Phase 3 ADMIRAL trial – an oral presentation on emerging mutations in patients who has develop resistance after an initial response to XOSPATA (gilteritinib) and also two poster presentations focused on patient-reported outcomes, as well as data on cost-effectiveness testing and treatment patterns and venetoclax combination therapy. https://www.astellas.com/en/news/15466
